← Eichor
Study identifier: NCT05701254 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Skeletal Effects of Type 1 Diabetes on Low-Trauma Fracture Risk

Condition: Type 1 Diabetes · Osteopenia · Bone Loss  ·  Sponsor: Creighton University

PhaseN/A
Planned participants80
Who can joinFemale, 50 Years to no upper limit
Healthy volunteersYes

About this study

Patients with Type 1 Diabetes Mellitus (T1DM) have a higher risk of low-trauma (osteoporotic) fracture that is 7-12 times higher than non-diabetics. The bone density of people with Type 1 Diabetes is higher at the time of fracture than in non-diabetics. This suggests the presence of underlying bone tissue mechanical defects. The potential benefits to participants would be knowledge gained about their bone density and the results of laboratory tests. On a wider scale, there may be general benefits to society because the knowledge gained from this study may help better understand the effects of diabetes on bone health

This description comes directly from the study's public registry record.

Talk to the study team

Adam Hornig  ·  402-559-9116  ·  adam.hornig@unmc.edu

Laura Armas, M.D.  ·  402-559-8700  ·  laura.armas@unmc.edu

Always discuss trial participation with your own doctor first.

Locations (1)

Creighton University Osteoporosis Research CenterOmaha, Nebraska, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05701254